ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Computational pharmacology-based molecular mechanism investigation of cinnamaldehyde intervention in nephrotic syndrome.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nephrotic syndrome (NS) is a common glomerular ailment caused by various factors and ranks as the second most frequently seen kidney disease. The study aims to investigate the potential therapeutic mechanism of cinnamaldehyde (CA) intervention in NS by utilizing computational pharmacology. Genes linked to NS were gathered from databases and then were used to construct a PPI network, of which the node importance values (Nim) were calculated utilizing an optimized algorithm. Functional enrichment analyses were performed to build a pathway network for NS. Afterward, CA's potential targets were acquired from the Venn diagram by intersecting NS-related genes and CA-related genes. The predicted targets and pathways of CA intervention in NS were identified using a mathematical algorithm that evaluated the disruption of NS pathways by CA, considering Nim, the number of pathways, and other variables. Molecular docking and cellular experiments were included in validation. By the way, the research collected 687 genes related to NS and 195 genes related to CA, which were used to identify 26 potential targets of CA in NS treatment. The disruption of 166 NS pathways by 26 CA targets was evaluated, showing that the Antifolate resistance and NOD-like receptor pathway exhibited the highest disturbance scores. Besides, key targets that were identified through the algorithm included IL1B, TNF, CASP8, and MAPK1, which were subsequently validated through molecular docking. Experimental results demonstrated that CA inhibited LPS-induced IL-1β, IL-6, and TNF-α levels in R264.7 cells and reduced p-38MAPK, p-ERK, and p-Caspase8 protein expression. This study proposes an algorithm for evaluating drug molecule perturbations on pathways. By employing this optimized model, potential key targets for CA in the treatment of NS are identified, with the anti-inflammatory effect potentially mediated through the Caspase8/MAPK pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.